natgillin/translations-raw huggingface dataset:
an outlet for agglomerates (8), and 
izlaz za aglomerate (8), i
Gasification reactor according to claim 9, characterised in that the height (h2) of the inlet (3) for feeding organic solid, measured in metres from the junction of the cylindrical section with the frustoconical section, is equal to the sine of angle β measured in degrees: h2= sinβ. 
Reaktor za rasplinjavanje u skladu s patentnim zahtjevom 9, naznačen time što visina (h2) ulaza (3) za dodavanje organskog čvrstog materijala, izmjerena u metrima od spoja valjkastog odjeljka s odjeljkom u obliku krnjeg stošca, je jednaka sinusu kuta β izmjerenog u stupnjevima: h2 = sinβ.
placing a form (400, 700) in a field of view of a camera, wherein the form (400, 700) includes thereon at least a first fiducial mark and a second fiducial mark (401b, 701b); 
stavljanje formulara (400, 700) u vidno polje kamere, gdje formular (400, 700) u sebi sadrži u najmanju ruku prvu položajnu oznaku i druga položajnu oznaku (401b, 701b);
wherein the outline portion ofthe first fiducial mark(401a,701a) is sufficiently different from the interior portion of the first fiducial mark (401a,701a) so as to result in the camera being capable of distinguishing between the outline portion and the interior portion; 
gdje je obrisni dio prve položajne oznake (401a,701a) dovoljno različit od unutarnjeg dijela prve položajne oznake (401a,701a) tako da kamera može praviti razliku između obrisnog dijela i unutarnjeg dijela;
detecting with the processor mechanism at least a first user marking cell on the form (400, 700) based at least in part upon the calculated distance between the first fiducial mark (401a,701a) and the second fiducial mark (401b, 701b), wherein the first user marking cell is bounded by at least one indicium that is visible to the camera; 
detektiranju procesorskim mehanizmom u najmanju ruku prve ćelije za korisničku oznaku na formularu (400, 700) na temelju u najmanju ruku dijelom izračunatog razmaka između prve položajne oznake (401a,701a) i druge položajne oznake (401b, 701b), gdje je prva ćelija za korisničku oznaku omeđena najmanje jednom bilješkom, vidljivom za kameru;
detecting with the processor mechanism at least a second user marking cell on the form (400, 700), wherein the second user marking cell is bounded by at least one indicium that is visible to the camera, and wherein the second user marking cell is detected based at least in part upon the displacement vector of the detected first user marking cell; 
detektiranju procesorskim mehanizmom u najmanju ruku druge ćelije za korisničku oznaku na formularu (400, 700), gdje je druga ćelija za korisničku oznaku omeđena najmanje jednom bilješkom, vidljivom za kameru, te gdje se drugu ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom vektora pomaka detektirane prve ćelije za korisničku oznaku;
calculating with the processor mechanism a displacement vector of the detected second user marking cell versus an ideal planar position of the detected second user marking cell; and detecting with the processor mechanism at least a third user marking cell on the form (400, 700), wherein the third user marking cell is bounded by at least one indicium that is visible to the camera, and wherein the third user marking cell is detected based at least in part upon at least one of: (a) the displacement vector of the detected first user marking cell; and (b) the displacement vector of the detected second user marking cell. 
izračunavanje procesorskim mehanizmom vektora pomaka detektirane druge ćelije za korisničku oznaku u odnosu na idealni planaran položaj detektirane druge ćelije za korisničku oznaku; i detektiranje procesorskim mehanizmom u najmanju ruku treće ćelije za korisničku oznaku na formularu (400, 700), gdje je treća ćelija za korisničku oznaku omeđena najmanje jednom bilješkom, vidljivom za kameru, te gdje se treću ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom najmanje jednog od: (a) vektora pomaka detektirane prve ćelije za korisničku oznaku; i (b) vektora pomaka detektirane druge ćelije za korisničku oznaku.
The method of claim 2, wherein the third user marking cell is detected based at least in part upon: (a) the displacement vector of the detected first user marking cell; and/or (b) the displacement vector of the detected second user marking cell. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se treću ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom: (a) vektora pomaka detektirane prve ćelije za korisničku oznaku; i/ili (b) vektora pomaka detektirane druge ćelije za korisničku oznaku.
detecting with the processor mechanism at least a third user marking cell on the form (400, 700), wherein the third user marking cell is bounded by an indicium that is visible to the camera, and wherein the third user marking cell is detected based at least in part upon at least one of: (a) a position of the detected first user marking cell; and (b) a position of the detected second user marking cell. The method of claim 6, further comprising: 
detektiranje procesorskim mehanizmom u najmanju ruku treće ćelije za korisničku oznaku na formularu (400, 700), gdje je treća ćelija za korisničku oznaku omeđena bilješkom vidljivom za kameru, te gdje se treću ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom najmanje jednog od: (a) položaja detektirane prve ćelije za korisničku oznaku; i (b) položaja detektirane druge ćelije za korisničku oznaku.
The method of claim 6, wherein the third user marking cell is detected based at least in part upon: (a) the position of the detected first user marking cell; and/or (b) the position of the detected second user marking cell. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se treću ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom: (a) položaja detektirane prve ćelije za korisničku oznaku; i/ili (b) položaja detektirane druge ćelije za korisničku oznaku.
The method of claim 1, wherein the camera comprises at least one lens. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što kamera sadrži najmanje jednu leću.
a processor mechanism in operative communication with the camera; and at least one form(400, 700), wherein the form includes thereon at least a first fiducial mark (401a,701a) and a second fiducial mark (401b,701b); 
procesorski mehanizam u radnoj komunikaciji s kamerom; i najmanje jedan formular (400, 700), gdje formular u sebi sadrži u najmanju ruku prvu položajnu oznaku (401a,701a) i drugu položajnu oznaku (401b,701b);
wherein the second fiducial mark (401b,701b) comprises an outline portion and an interior portion; wherein the outline portion of the second fiducial mark (401b,701b) is sufficiently different from the interior portion of the second fiducial mark (401b,701b) so as to result in the camera being capable of distinguishing between the outline portion and the interior portion; and 
gdje je obrisni dio druge položajne oznake (401b,701b) dovoljno različit od unutarnjeg dijela druge položajne oznake (401b,701b) tako da kamera može praviti razliku između obrisnog dijela i unutarnjeg dijela; i gdje, kada se formular (400, 700) stavi u vidno polje kamere, kamera i procesorski mehanizam se prilagode za izvršavanje sljedećih koraka:
generating, with the camera, an electronic image of at least a portion of the form (400, 700); 
dobivanja, kamerom, elektronske slike u najmanju ruku dijela formulara (400, 700);
detecting with the processor mechanism at least a first user marking cell on the form (400, 700) based at least in part upon the calculated distance between the first fiducial mark (401a,701a) and the second fiducial mark (401b,701b), wherein the first user marking cell is bounded by at least one indicium that is visible to the camera; 
detektiranja procesorskim mehanizmom u najmanju ruku prve ćelije za korisničku oznaku na formularu (400, 700) na temelju u najmanju ruku dijelom izračunatog razmaka između prve položajne oznake (401a,701a) i druge položajne oznake (401b,701b), gdje je prva ćelija za korisničku oznaku omeđena najmanje jednom bilješkom, vidljivom za kameru;
detecting with the processor mechanism at least a second user marking cell on the form (400, 700), wherein the second user marking cell is bounded by at least one indicium that is visible to the camera, and wherein the second user marking cell is detected based at least in part upon the displacement vector of the detected first user marking cell; 
detektiranja procesorskim mehanizmom u najmanju ruku druge ćelije za korisničku oznaku na formularu (400, 700), gdje je druga ćelija za korisničku oznaku omeđena najmanje jednom bilješkom, vidljivom za kameru, te gdje se drugu ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom vektora pomaka detektirane prve ćelije za korisničku oznaku;
The system of claim 12, wherein the camera comprises at least one image sensor. 
Sustav u skladu s patentnim zahtjevom 12, naznačen time što kamera sadrži najmanje jedan senzor slike.
The system of claim 12, wherein the form (400, 700) is non-planar. 
Sustav u skladu s patentnim zahtjevom 12, naznačen time što formular (400, 700) nije planaran.
A process for gasification of organic solid materials in a fluidised bed reactor (1) by means of a circulating gas flow containing solid fluidised material particles, comprising: 
Postupak rasplinjavanja organskih čvrstih materijala u reaktoru s fluidiziranim slojem (1) cirkuliranjem struje plina koja sadrži čestice čvrstog fluidiziranog materijala, koji se sastoji u:
b.-) providing a catalytic agent or mixture thereof with inert material through an inlet (7), 
-) dobavu katalitičkog sredstva ili njegove smjese s inertnim materijalom kroz ulaz (7),
Gasification reactor according to claim 9, characterised in that it comprises the following outlets for material: 
Reaktor za rasplinjavanje u skladu s patentnim zahtjevom 9, naznačen time što sadrži sljedeće izlaze za materijal:
at least one drug selected from the group consisting of a serotonin reuptake inhibitor and a serotonin and norepinephrine reuptake inhibitor; 
najmanje jedan lijek odabran iz skupine koja se sastoji od inhibitora povratne apsorpcije serotonina, i inhibitora povratne apsorpcije serotonina i noradrenalina;
The medicament of claim 1, wherein the medicament comprises a composition comprising said compound of (I) and a composition comprising said drug of (II), which are separately formulated, and the composition of said compound of (I) is provided for use in combination with the composition of said drug of (II). 
Medikament prema zahtjevu 1, naznačen time, da medikament obuhvaća jedan sastav koji obuhvaća navedeni spoj (I) i jedan sastav koji obuhvaća navedeni lijek (II), koji su formulirani odvojeno, te se sastav od navedenog spoja (I) pripravlja za uporabu u kombinaciji sa sastavom od navedenog lijeka (II).
The medicament of any one of claims 1 to 3, wherein said drug of (II) is a serotonin reuptake inhibitor, which is at least one drug selected from the group consisting of fluoxetine, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof. 
Medikament prema bilo kojem od zahtjeva 1 do 3, naznačen time, da se kod navedenog lijeka (II) radi o inhibitoru povratne apsorpcije serotonina, koji je najmanje jedan lijek odabaran iz skupine koju čine fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram i njihove soli.
The medicament of any one of claims 1 to 3, wherein said drug of (II) is a serotonin and norepinephrine reuptake inhibitor, which is at least one drug selected from the group consisting of venlafaxine, duloxetine, milnacipran, desvenlafaxine and salts thereof. 
Medikament prema bilo kojem od zahtjeva 1 do 3, naznačen time, da se kod navedenog lijeka (II) radi o inhibitoru povratne apsorpcije serotonina i noradrenalina, koji je najmanje jedan lijek odabaran iz skupine koju čine venlafaksin, duloksetin, milnacipran, desvenlafaksin i njihove soli.
wherein said serotonin reuptake inhibitor is at least one drug selected from the group consisting of fluoxetine, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof, and said serotonin and norepinephrine reuptake inhibitor is at least one drug selected from the group consisting of venlafaxine, duloxetine, milnacipran, desvenlafaxine and salts thereof. 
pri čemu je navedeni inhibitor povratne apsorpcije serotonina najmanje jedan lijek odabaran iz skupine koju čine fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram i njihove soli, dok je navedeni inhibitor povratne apsorpcije serotonina i noradrenalina najmanje jedan lijek odabran iz skupine koju čine venlafaksin, duloksetin, milnacipran, desvenlafaksin i njihove soli.
A delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at pH 6.5 or above, and wherein the inner layer comprises a third polymeric material which is soluble in intestinal fluid, said third polymeric being a polycarboxylic acid polymer that is at least partially neutralised, wherein at least 10% of the carboxylic acid groups of the polycarboxylic acid polymer are in the form of carboxylate anions. 
Formulacije lijeka s produljenim oslobađanjem za oralnu primjenu za isporuku lijeka u debelo crijevo pacijenta, pri čemu spomenuta formulacija sadrži jezgro, to jezgro sadrži lijek i prevlaku za jezgru, jezgru koja sadrži lijek i ovojnicu koja sadrži vanjski i unutarnji sloj, pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima graničnu vrijednost pH na pH 6,5 ili više, i pri čemu unutarnji sloj sadrži treći polimerni materijal koji je topiv u crijevnoj tekućini, spomenuti treći polimerni materijal je polimer polikarboksilne kiseline koji je bar djelomično neutraliziran, pri čemu bar 10% skupina karboksilne kiseline polimera polikarboksilne kiseline su u obliku aniona karboksilata.
A delayed release drug formulation as claimed in Claim 1, wherein at least 90 % of the carboxylic acid groups of the polycarboxylic acid polymer are in the form carboxylate anions. 
Polimer polikarboksilne kiseline koji je bar djelomično neutraliziran, pri čemu bar 90 % skupina karboksilne kiseline polimera polikarboksilne kiseline su u obliku anjona karboksilata.
A delayed release drug formulation as claimed in Claim 1 or Claim 2, wherein the third polymeric material is fully neutralised. 
Formulacija lijeka s produljenim oslobađanjem za koju se traži zaštita patentom u patentnom zahtjevu 1 ili patentnom zahtjevu 2, pri čemu je treći polimerni materijal potpuno neutraliziran.
A delayed release drug formulation as claimed in any of the preceding claims, wherein the inner layer comprises a buffer agent selected from an inorganic salt or a pharmacologically acceptable carboxylic acid having from 1 to 16 carbon atoms. 
Formulacija lijeka s produljenim oslobađanjem za koju se traži zaštita patentom u bilo kojem od prethodnih patentnih zahtjeva, pri čemu unutarnji sloj sadrži puferski agens odabran iz anorganske soli ili farmaceutski prihvatljive karboksilne kiseline koja ima od 1 do 16 atoma ugljika.
coating the core using an inner coating preparation comprising a third polymeric material that is soluble in intestinal fluid, in a solvent system to form an inner coated core; and coating the inner coated core with an outer coating preparation comprising a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold of pH 6.5 or above in a solvent system, to form an outer coated core; 
oblaganje jezgre upotrebom unutarnjeg preparata za oblaganje sadrži treći polimerni materijal koji je topiv u crijevnoj tekućini, u sustavu otapala da se formira unutrašnje obložena jezgra; i oblaganje unutarnje obložene jezgre s vanjskim premaznim pripravkom sadrži prvi polimerni materijal koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima pH granicu od pH 6,5 ili više u sustavu otapala, da se dobije vanjska obložena jezgra;
wherein said third polymeric material is a polycarboxylic acid polymer that is at least partially neutralised, wherein at least 10% of the carboxylic acid groups of the polycarboxylic acid polymer are in the form of carboxylate anions. 
pri čemu je spomenuti treći polimerni materijal je polimer polikarboksilne kiseline koji je barem djelimično neutraliziran, pri čemu najmanje 10% skupina karboksilne kiseline polimera polikarboksilne kiseline su u obliku aniona karboksilata.
The apparatus according to claim 1, wherein at least one of the mould parts comprises refrigerating means for freezing liquid substance inside the mould (8, 8) and heating means for detaching an obtained ice column from the mould by melting. The apparatus according to claim 11, wherein said heating means comprises an electrical heating element. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što najmanje jedan od dijelova kalupa sadrži element za smrzavanje, namijenjen smrzavanju tekuće tvari unutar kalupa (8, 8), i element za grijanje, namijenjen odvajanju dobivenog stupca leda od kalupa taljenjem.
assessing the level of lactoferrin in the saliva or in a saliva sample of said subject, and 
procjenu razine laktoferina u uzorku sline dobivenom od navedenog subjekta, i
in raising an immune response against Pseudomonas aeruginosa infections in a mammal; or 
za podizanju imunog odgovora protiv infekcija Pseudomonas aeruginosa kod ljudi; ili
as a prophylactic or therapeutic vaccine against nosocomial infections caused by Pseudomonas aeruginosa. 
kao profilaktičko ili terapeutsko cjepivo protiv nozokomijalnih infekcija izazvanih s Pseudomonas aeruginosa.
A porcelain pot according to Claim 1, characterized in that the raw materials of said structure formula consists only of 0,2 Na2O, 0,4 K2O, 0,2 CaO, 0,2 MgO, 6,1 Al2O3 and 25,2 SiO2 according to Seger formula. 
Porculanski lonac sukladno patentnom zahtjevu 1, naznačen time što sirovine navedene strukturne formule sadrže samo 0,2 Na2O, 0,4 K2O, 0,2 CaO, 0,2 MgO, 6,1 Al2O3 i 25,2 SiO2 u skladu sa Zegerovom formulom.
A porcelain pot according to Claim 1, characterized in that the raw materials of said glaze formula consists only of 0,2 Na2O, 0,1 K2O, 0,4 CaO, 0,3 MgO, 0,1 Al2O3 and 4,6 SiO2 according to Seger formula. 
Porculanski lonac sukladno patentnom zahtjevu 1, naznačen time što sirovine navedene formule glaziranja sarže samo 0,2 Na2O, 0,1 K2O, 0,4 CaO, 0,3 MgO, 0,1 Al2O3 i 4,6 SiO2 u skladu sa Zegerovom formulom.
A porcelain pot manufacture method according to Claim 4, characterized in that it comprises the process step of shaping (2) after the said process of loading structure formula (1). 
Postupak proizvodnje porculanskog lonca sukladno patentnom zahtjevu 4, naznačen time što obuhvaća korak postupka oblikovanja (2) poslije navedenog postupka učitavanja strukturne formule (1).
A porcelain pot manufacture method according to Claims 4 and 5, characterized in that it comprises the process step of drying (3) after said process of shaping (2). 
Postupak proizvodnje porculanskog lonca u skladu s patentnim zahtjevima 4 i 5, naznačen time što sadrži korak postupka sušenja (3) poslije navedenog postupka oblikovanja (2).
A porcelain pot manufacture method according to Claim 4, characterized in that it comprises the process step of weighing the content and filtering thereof during the process of loading formula (1). 
Postupak proizvodnje porculanskog lonca u skladu s patentnim zahtjevom 4, naznačen time što sadrži korak postupka mjerenja i filtriranja sadržaja tokom postupka učitavanja formule (1).
A porcelain pot manufacture method according to Claim 4, characterized in that it comprises the process steps of weighing the raw materials and filtering thereof during the process of loading glaze formula (5). 
Postupak proizvodnje porculanskog lonca u skladu s patentnim zahtjevom 4, naznačen time što sadrži korak postupka mjerenja i filtriranja sirovina tokom postupka učitavanja formule (5) glaziranja.
A porcelain pot manufacture method according to Claim 4, characterized in that it comprises the process step of glazing (6) the material subject to biscuit firing (5) process, by plunging into the glaze prepared during loading glaze formula (5). 
Postupak proizvodnje porculanskog lonca u skladu s patentnim zahtjevom 4, naznačen time što sadrži korak postupka glaziranja (6) materijala koji se podvrgava postupku prvog pečenja (5), uranjanjem u glazuru pripremljenu tokom učitavanja formule (5) glaziranja.
A porcelain pot manufacture method according to Claim 4, characterized in that the said glazed firing (7) process is performed at 1420 °C and/or for 7 hours. 
Postupak proizvodnje porculanskog lonca u skladu s patentnim zahtjevom 4, naznačen time što se navedeni postupak pečenja (7) glaziranog materijala izvodi na1420°C i/ili tokom 7 sati.
An anti-HIV antibody, wherein said antibody is PG9 having a heavy chain comprising the amino acid sequence of SEQ ID NO: 39 and a light chain comprising the amino acid sequence of SEQ ID NO: 40. 
Protutijelo protiv HIV-a, naznačeno time što je navedeno protutijelo PG9, koji ima teški lanac, koji sadrži aminokiselinski slijed SEQ ID NO: 39, i laki lanac, koji sadrži aminokiselinski slijed SEQ ID NO: 40.
The antibody according to claim 4, wherein the antibody (a) neutralizes at least one member of each clade with a potency greater than that of the bNAbs b12, 2G12, 2F5 and 4E10 respectively, (b) does not bind monomeric gp120 or gp41 proteins of the HIV-1 env gene or (c) binds with higher affinity to trimeric forms of the HIV-1 Env expressed on a cell surface than to the monomeric gp120 or artificially trimerized gp140. 
Protutijelo u skladu s patentnim zahtjevom 4, naznačeno time što protutijelo (a) neutralizira najmanje jedan član svakog klada s potentnošću većom od one za bNAbs b12, 2G12, 2F5 odnosno 4E10, (b) ne veže se na monomerne proteine gp120 ili gp41 iz HIV-1 env gena ili (c) veže se većim afinitetom prema trimernim oblicima HIV-1 Env koji se eksprimiraju na površini stanice nego prema monomernom gp120 ili gp140 trimeriziranom na umjetan način.
The antibody according to claim 6, wherein the antibody binds with high affinity to uncleaved HIV-1 gp160 trimers on a cell surface. 
Protutijelo u skladu s patentnim zahtjevom 6, naznačeno time što se protutijelo veže s visokim afinitetom na necijepane HIV-1 trimere gp160 na površini stanice.
The antibody according to claim 8, wherein the antibody does not neutralize the HIV-1 in the absence of N-glycosylation site at residue Asn-160 within the V2 loop of gp120. 
Protutijelo u skladu s patentnim zahtjevom 8, naznačen time što protutijelo ne neutralizira HIV-1 u odsutnosti N-glikozilacijskog mjesta na ostatku Asn-160 u omči V2 u gp120.
The antibody according to any of claims 3 to 6, wherein the antibody binds an epitope presented by a trimeric spike of gp120 on a cell surface, wherein the epitope is not presented when gp120 is artificially trimerized. 
Protutijelo u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačeno time što se protutijelo veže na epitop kojeg prezentira trimerni šiljak gp120 na površini stanice, gdje se epitop ne prezentira kada je gp120 trimeriziran na umjetan način.